Are all quantitative postmarketing signal detection methods equal? Performance characteristics of logistic regression and Multi-item Gamma Poisson Shrinker

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 6, 2012, Pages 622-630

  Berlin, Conny ^a   Blanch, Carles ^a   Lewis, David J ^a   Maladorno, Dionigi D ^a   Michel, Christiane ^a   Petrin, Michael ^a   Sarp, Severine ^a   Close, Philippe ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Disproportionality; Performance characteristics; Signal detection

Indexed keywords

ALISKIREN; CLOMIPRAMINE; CLOZAPINE; DEFERASIROX; FORMOTEROL; LETROZOLE; MAPROTILINE; NILOTINIB; RANIBIZUMAB; RIVASTIGMINE; TELBIVUDINE; TIZANIDINE; VILDAGLIPTIN; ZOLEDRONIC ACID;

ALGORITHM; ANEMIA; ARTICLE; ASTHMA; BREAST CANCER; CHRONIC DISEASE; CHRONIC MYELOID LEUKEMIA; COUGHING; DEMENTIA; DEPRESSION; DRUG ERUPTION; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EMPIRICAL BAYES MULTI ITEM GAMMA POISSON SHRINKER; HEPATITIS B; HUMAN; HYPERCALCEMIA; HYPERTENSION; IRON OVERLOAD; LOGISTIC REGRESSION ANALYSIS; MUSCLE SPASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINA MACULA AGE RELATED DEGENERATION; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SIGNAL DETECTION; SPASTICITY; STANDARD;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ALGORITHMS; BAYES THEOREM; COMPUTER SIMULATION; DATA MINING; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; POISSON DISTRIBUTION; PREDICTIVE VALUE OF TESTS; PRODUCT SURVEILLANCE, POSTMARKETING; SENSITIVITY AND SPECIFICITY;

EID: 84862235503     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2247     Document Type: Article

References (19)

1. Szarfman A, Machado S, O'Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database. Drug Safety 2002; 25(6): 381-392.
2. Hopstadius J, Norén N, Bate A, et al. Impact of stratification on adverse drug reaction surveillance. Drug Safety 2008; 31(11): 1035-1048.
3. Egberts A, Meyboom R, van Puijenbroek E. Use of measures of disproportionality in pharmacovigilance. Drug Safety 2002; 25(6): 453-458.
4. Czarnecki A, Voss S. Safety signals using proportional reporting ratios from company and regulatory authority databases. Drug Information Journal 2008; 42: 205-210.
5. Lehman HP, Chen J, Kassekert R, Beninger PR, et al. An Evaluation of computer-aided disproportionality analysis for post-marketing signal detection. Clin Pharmacol Ther 2007; 82(2): 173-180.
6. Hauben M. Data Mining in Pharmacovigilance: The Need for a Balanced Perspective. Drug Safety 2005; 28(10): 835-842.
7. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRR) for signal generation from spontaneous adverse drug reactions reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-486.
8. DuMouchel W, Yang X, Mahmoud R, et al. Antipsychotics, glycaemic disorders, and life-threatening diabetic events: A Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Annals of Clinical Psychiatry 2008; 20(1): 21-31.
9. Bate A, Lindquis Mt, Edwards LR, et al. A data mining approach for signal detection and analysis. Drug Safety 2002; 25(6): 393-7.
10. Du Mouchel W, Smith T, Beasley R, et al. Association of asthma therapy and Churg-Strauss syndrome: an analysis of post-marketing surveillance. Clin Ther 2004; 26: 1092-1104.
11. Rothman K, Lanes S, Sacks S. The reporting odds ratios and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004; 13: 519-523.
12. Almenoff JS, LaCroix K, Yen N, et al. Comparative performance of two quantitative safety signaling methods. Drug Safety 2006; 29(10): 875-887.
13. th March 2010).
14. th April 2011)
15. Szarfman A, Machado SG, O'Neill RT. Use of Screening Algorithms and Computer Systems to Efficiently Signal Higher-Than-Expected Combinations of Drugs and Events in the US FDA's Spontaneous Database. Drug Safety 2002; 25(6): 381-392.
16. O'Neill RT. Assessment of Safety. In Biopharmaceutical statistics for drug development, Pearce KE (eds.). New York and Basel: Marcel Dekker, 1988; 543-605.
17. th April 2010).
18. Seabroke S. Update on EmpiricaTM Signal at the MHRA. Phase Forward European Users Conference: London, 2009.
19. Matsushita Y, Kuroda Y, Niwa S, et al. Criteria revision and performance comparison of three methods of signal detection. Drug Safety 2007; 30(8): 715-26.